Related Experiment Video
Updated: Sep 10, 2025
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
Novel Macrolide Antibiotic Nafithromycin for Tackling Emerging Resistance in Respiratory Pathogens Encountered in
Swati Paliwal1,2, Kajal Chaudhary2, Uma Agarwal3,4
1Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, Pushp ViharSector-3, M-B Road, New Delhi, 110017, India.
Abstract:
Nafithromycin (WCK 4873), is India's first approved macrolide antibiotic by DCGI(Drug Controller General of India), represents a significant advancement in combating antimicrobial resistance (AMR) and multidrug-resistant (MDR) pathogens. After three decades of research and development, supported by BIRAC, Wockhardt Ltd. successfully developed this innovative lactone- ketolide antibiotic which demonstrates superior efficacy against respiratory pathogens, particularly drug-resistant Streptococcus pneumoniae. Its unique structural modifications at the C-3 position and enhanced side chain configurations improve its pharmacological profile compared to previous generation macrolides. Nafithromycin binds to both domains II and V of 23 s rRna, thereby circumventing the resistance mechanisms which impacts older macrolide due to their single target binding. Owing to dual binding of nafithromycin, it is more potent than the older macrolides. Additionally, nafithromycin exhibits immunomodulatory effects in acute lung injury models, suggesting potential therapeutic benefits beyond its antimicrobial activity. Moreover, Phase I and II trials demonstrate its safety and tolerability, with minimal drug-drug interactions due to reduced CYP3A4/5 inhibition. Phase III results show that nafithromycin is effective against a wide variety of respiratory infections as well as intracellular atypical pathogens which can be difficult to treat other ways. No significant AEs were encountered. In this comprehensive review, the adverse effects of other antibiotics are examined, along with the benefits of nafithromycin over other medications, its development, mechanism of action, structure-activity relationships, clinical efficacy, drug delivery strategies via various routes to overcome antimicrobial resistance, strategies to combat antimicrobial resistance, and future perspectives in addressing the global antimicrobial resistance challenges.
Insights
Nafithromycin, India's first novel macrolide antibiotic, shows enhanced efficacy against drug-resistant bacteria by dual binding to rRNA. This advancement offers a potent new weapon against antimicrobial resistance (AMR).
Area of Science:
- Pharmacology and Microbiology
- Drug Discovery and Development
- Infectious Diseases
Background:
- Antimicrobial resistance (AMR) poses a significant global health threat, necessitating novel therapeutic agents.
- Existing macrolide antibiotics face challenges due to emerging resistance mechanisms.
- Nafithromycin (WCK 4873) emerged as a potential solution after extensive research and development.
Purpose of the Study:
- To review the development, mechanism of action, and clinical efficacy of nafithromycin.
- To compare nafithromycin's benefits against other antibiotics, particularly for respiratory and multidrug-resistant pathogens.
- To explore nafithromycin's potential in combating antimicrobial resistance.
Main Methods:
- Review of preclinical and clinical trial data (Phase I, II, and III) for nafithromycin.
- Analysis of structural modifications and their impact on pharmacological profile and mechanism of action.
- Examination of safety, tolerability, and adverse effect profiles compared to existing antibiotics.
Main Results:
- Nafithromycin demonstrates superior efficacy against drug-resistant Streptococcus pneumoniae and other respiratory pathogens.
- Dual binding to 23S rRNA domains II and V circumvents common macrolide resistance mechanisms.
- Clinical trials indicate safety, tolerability, minimal drug-drug interactions, and effectiveness against atypical pathogens.
Conclusions:
- Nafithromycin represents a significant advancement in combating antimicrobial resistance (AMR) and multidrug-resistant (MDR) pathogens.
- Its unique dual-binding mechanism and favorable safety profile offer advantages over older macrolides.
- Nafithromycin holds promise for treating a wide range of infections, including those caused by difficult-to-treat pathogens.
Related Concept Videos
01:30Development of Antibiotic Resistance
01:28Antimicrobial Effectiveness
00:57Antibiotic Selection
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...